Sensorium Therapeutics
PrivateLast Round
Series A
Extension
Aug 20, 2025
Total Funding Raised
$55M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Sensorium Therapeutics is a biotechnology company that develops nature-derived psychoactive medicines for mental and brain health conditions using its proprietary AI-driven discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sensorium Therapeutics Comparables
Compare Sensorium Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mindstate Design Labs | 87% | |
| Otsuka Holdings | 84% | |
| Delix Therapeutics | 83% |
Sensorium Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Aug 20, 2025 | ||||
| Series A | Nov 8, 2022 |
Key People
Founding team and executive leadership
Sensorium Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dolby Family Ventures | Series A Extension |
| H. Barton Asset Management | Series A Extension |
| Hatteras Venture Partners | Series A Extension |
| re.Mind Capital | Series A |
| Iter Investments | Series A |
| Mockingbird Capital Partners | Series A Extension |
| Palo Santo | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 39% MoM.
- Jul 9, 2025
Jacob Hooker, PhD, appointed as new Chief Executive Officer.
Recent news
Latest coverage and updates
- attends_eventAug 19, 2026
Sensorium Therapeutics will attend event Psych Congress 2026 on Sep 15th '26.
Sensorium Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Sensorium Therapeutics's valuation, stock price, and market status.
Is Sensorium Therapeutics a public or private company?
Sensorium Therapeutics is a private company.
What is the current stock price of Sensorium Therapeutics?
Sensorium Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Sensorium Therapeutics worth (valuation)?
Valuation information for Sensorium Therapeutics is not publicly available.
Can I buy Sensorium Therapeutics stock?
Sensorium Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Sensorium Therapeutics's last funding round?
Sensorium Therapeutics's most recent funding round was Series A Extension on August 20, 2025.
Who are the main investors in Sensorium Therapeutics?
Key investors in Sensorium Therapeutics include Dolby Family Ventures, Hatteras Venture Partners, Mockingbird Capital Partners, Santé Ventures.
Will Sensorium Therapeutics IPO soon?
No public IPO plans have been announced for Sensorium Therapeutics.
How can I track Sensorium Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Sensorium Therapeutics's secondary market activity and sign up for updates.